These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18165702)

  • 1. Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert.
    Torresi U
    Ann Oncol; 2008 Jan; 19(1):191. PubMed ID: 18165702
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.
    Puente Vázquez J; López-Tarruella Cobo S; García-Sáenz JA; Casado Herráez A; Moreno Antón F; Sampedro Gimeno T; Bueno Muiño C; Grande Pulido E; Martín Jiménez M; Díaz-Rubio E
    Clin Transl Oncol; 2006 Jan; 8(1):50-3. PubMed ID: 16632440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral metastases in patients with advanced breast cancer treated with trastuzumab.
    Atkinson J; Peace J; Crawford SM
    Am J Clin Oncol; 2004 Apr; 27(2):212. PubMed ID: 15057165
    [No Abstract]   [Full Text] [Related]  

  • 4. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
    Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
    Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
    Callahan R; Hurvitz S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):37-43. PubMed ID: 21500375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence and treatment outcome after radiotherapy for brain metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab.
    Arif S; Barrett-Lee PJ; Jordan C
    Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):719-20. PubMed ID: 17100160
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab treatment beyond brain progression in HER2- positive metastatic breast cancer.
    Kilickap S; Arslan C
    Ann Oncol; 2009 Jan; 20(1):192. PubMed ID: 19172706
    [No Abstract]   [Full Text] [Related]  

  • 10. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
    Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
    Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
    Colozza M; Minenza E; Gori S; Fenocchio D; Paolucci C; Aristei C; Floridi P
    Cancer Chemother Pharmacol; 2009 May; 63(6):1157-9. PubMed ID: 18987856
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
    Isakoff SJ; Baselga J
    J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881
    [No Abstract]   [Full Text] [Related]  

  • 14. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on: incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
    Errante D; Bernardi D; Bianco A; Salvagno L
    Acta Oncol; 2007; 46(4):565-6. PubMed ID: 17497328
    [No Abstract]   [Full Text] [Related]  

  • 17. HER2 testing recommendations in Australia.
    Bilous M;
    Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

  • 20. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.